mRNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA nanostructures to better control how the immune system responds. In early studies, it produced strong antibody and T cell responses in both mice and human models. Researchers say it could lead to more stable, easier-to-manufacture vaccines for diseases like COVID-19, HIV, and Ebola.